Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma

John P. Leonard, Stephanie A. Gregory, David G. Maloney, Julie Marie Vose, Anas Younes, Andrew D. Zelenetz

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Indolent non-Hodgkin lymphomas (NHLs) are among the most prevalent hematologic malignancies; their incidence has been increasing over the last several decades. Because advanced-stage indolent lymphoma is generally incurable, therapy for this group of patients is geared toward chronic management over years. Recently, numerous trials have demonstrated that the combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab can provide superior efficacy to chemotherapy alone. Thus, rituximab-containing regimens are the standard approach for primary therapy in patients with symptomatic advanced disease. As these patients progress and receive multiple rituximab-based regimens over time, new treatment options are needed for this new group of rituximab-pretreated patients. This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL.

Original languageEnglish (US)
Pages (from-to)437-445
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume6
Issue number6
StatePublished - Jun 1 2008

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Hematologic Neoplasms
Group Psychotherapy
Combination Drug Therapy
Lymphoma
Monoclonal Antibodies
Rituximab
Drug Therapy
Incidence

Keywords

  • Bendamustine
  • Bortezomib
  • Lenalidomide
  • Non-Hodgkin lymphoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. / Leonard, John P.; Gregory, Stephanie A.; Maloney, David G.; Vose, Julie Marie; Younes, Anas; Zelenetz, Andrew D.

In: Clinical Advances in Hematology and Oncology, Vol. 6, No. 6, 01.06.2008, p. 437-445.

Research output: Contribution to journalReview article

Leonard, John P. ; Gregory, Stephanie A. ; Maloney, David G. ; Vose, Julie Marie ; Younes, Anas ; Zelenetz, Andrew D. / Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. In: Clinical Advances in Hematology and Oncology. 2008 ; Vol. 6, No. 6. pp. 437-445.
@article{0294ae0fe18e4b68b8d062d889302578,
title = "Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma",
abstract = "Indolent non-Hodgkin lymphomas (NHLs) are among the most prevalent hematologic malignancies; their incidence has been increasing over the last several decades. Because advanced-stage indolent lymphoma is generally incurable, therapy for this group of patients is geared toward chronic management over years. Recently, numerous trials have demonstrated that the combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab can provide superior efficacy to chemotherapy alone. Thus, rituximab-containing regimens are the standard approach for primary therapy in patients with symptomatic advanced disease. As these patients progress and receive multiple rituximab-based regimens over time, new treatment options are needed for this new group of rituximab-pretreated patients. This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL.",
keywords = "Bendamustine, Bortezomib, Lenalidomide, Non-Hodgkin lymphoma, Radioimmunotherapy",
author = "Leonard, {John P.} and Gregory, {Stephanie A.} and Maloney, {David G.} and Vose, {Julie Marie} and Anas Younes and Zelenetz, {Andrew D.}",
year = "2008",
month = "6",
day = "1",
language = "English (US)",
volume = "6",
pages = "437--445",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "6",

}

TY - JOUR

T1 - Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma

AU - Leonard, John P.

AU - Gregory, Stephanie A.

AU - Maloney, David G.

AU - Vose, Julie Marie

AU - Younes, Anas

AU - Zelenetz, Andrew D.

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Indolent non-Hodgkin lymphomas (NHLs) are among the most prevalent hematologic malignancies; their incidence has been increasing over the last several decades. Because advanced-stage indolent lymphoma is generally incurable, therapy for this group of patients is geared toward chronic management over years. Recently, numerous trials have demonstrated that the combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab can provide superior efficacy to chemotherapy alone. Thus, rituximab-containing regimens are the standard approach for primary therapy in patients with symptomatic advanced disease. As these patients progress and receive multiple rituximab-based regimens over time, new treatment options are needed for this new group of rituximab-pretreated patients. This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL.

AB - Indolent non-Hodgkin lymphomas (NHLs) are among the most prevalent hematologic malignancies; their incidence has been increasing over the last several decades. Because advanced-stage indolent lymphoma is generally incurable, therapy for this group of patients is geared toward chronic management over years. Recently, numerous trials have demonstrated that the combination of chemotherapy and the anti-CD20 monoclonal antibody rituximab can provide superior efficacy to chemotherapy alone. Thus, rituximab-containing regimens are the standard approach for primary therapy in patients with symptomatic advanced disease. As these patients progress and receive multiple rituximab-based regimens over time, new treatment options are needed for this new group of rituximab-pretreated patients. This review focuses on the development of novel therapies for rituximab-pretreated, relapsed or refractory indolent NHL.

KW - Bendamustine

KW - Bortezomib

KW - Lenalidomide

KW - Non-Hodgkin lymphoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=52949089961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949089961&partnerID=8YFLogxK

M3 - Review article

C2 - 18567989

AN - SCOPUS:52949089961

VL - 6

SP - 437

EP - 445

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 6

ER -